Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis

Multiple Sclerosis Journal

Volumn 17, Issue 5, 2011, Pages 521-531

  Correale, Jorge ^a   Fiol, Marcela ^a  

^a FLENI   (Argentina)

Author keywords

Chemokines; Chitinases; Devic'disease; Multiple sclerosis; Neuromyelitis optica

Indexed keywords

ACID MAMMALIAN CHITINASE; CHITINASE; CHITINASE 3 LIKE I; CHITOTRIOSIDASE; EOTAXIN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; UNCLASSIFIED DRUG; BETA N ACETYLHEXOSAMINIDASE; BIOLOGICAL MARKER; CHEMOKINE; CHI3L1 PROTEIN, HUMAN; CHIA PROTEIN, HUMAN; CYTOKINE; GLYCOPROTEIN; LECTIN; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BLOOD LEVEL; CELL MIGRATION; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EOSINOPHIL; FEMALE; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; RELAPSE; REMISSION; T LYMPHOCYTE; ARGENTINA; BLOOD; CASE CONTROL STUDY; CELL CULTURE; CEREBROSPINAL FLUID; COCULTURE; ENDOTHELIUM CELL; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; UPREGULATION;

ADULT; ARGENTINA; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; CASE-CONTROL STUDIES; CELLS, CULTURED; CHEMOKINES; CHITINASE; COCULTURE TECHNIQUES; CYTOKINES; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GLYCOPROTEINS; HEXOSAMINIDASES; HUMANS; LECTINS; LEUKOCYTES, MONONUCLEAR; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN-ASSOCIATED GLYCOPROTEIN; NEUROMYELITIS OPTICA; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; UP-REGULATION;

EID: 80053425015     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458510392619     Document Type: Article

References (42)

1. Nair MG, Guild KJ and Artis D. Novel effector molecules in type 2 inflammation: lessons drawn from helminth infection and allergy. J Immunol 2006; 177: 1393-1399. (Pubitemid 44092469)
2. Kawada M, Hachiya Y and Mizoguchi E. Role of the mammalian chitinases in inflammatory conditions. Keio J Med 2007; 56: 21-27. (Pubitemid 46588469)
3. Jin HM, Copeland NG, Gilbert DJ, Jenkins NA, Kirkpatrick RB and Rosenberg M. Genetic characterization of a cluster of highly homologous genes. Genomics 1998; 276: 2198-2202.
4. Zhu Z, Zheng T, Homer RJ, Kim YK, Chen NY, Cohn L, et al. Acid mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 2004; 304: 1678-1682. (Pubitemid 38765861)
5. Mizoguchi E. Chitinase 3-like-1 exacerbates intestinal inflammation by enhancing bacterial adhesion and invasion in colonic epithelial cells. Gastroenterol 2006; 130: 398-411. (Pubitemid 43202039)
6. Comabella M, Fernandez M, Martin R, Rivera-Vallvé S, Borrás E, Chiva C, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010; 133: 1082-1093.
7. Recklies AD, White C and Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 2002; 365: 119-126. (Pubitemid 34756146)
8. Nishikawa KC and Millis AJ. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cells Res 2003; 287: 79-87. (Pubitemid 36683203)
9. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231. (Pubitemid 13158528)
10. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
11. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF and Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489. (Pubitemid 43958540)
12. Correale J, Rush C, Amengual A and Goicochea MT. Mitoxantrone as rescue therapy in worsening relapsingremitting MS patients receiving IFN-beta. J Neuroimmunol 2005; 162: 173-183.
13. Alter A, Duddy M, Hebert S, Biernacki K, Prat A, Antel JP, et al. Determinants of human B cell migration across brain endothelial cells. J Immunol 2003; 170: 4497-4505. (Pubitemid 36522744)
14. Boot RG, Renkema GH, Strijland A, van Zonneveld AJ and Aerts JM. Cloning of cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem 1995; 270: 26252-26256.
15. van Eijk M, van Roomen CP, Renkema GH, Bussink AP, Andrews L, Blommaart EF, et al. Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int Immunol 2005; 17: 1505-1512. (Pubitemid 41631326)
16. Barone R, Di Gregorio F, Romeo MA, Schiliro G and Pavone L. Plasma chitotriosidase activity in patients with beta thalassemia. Blood Cell Mol Dis 1999; 25: 1-8. (Pubitemid 29205485)
17. Hollak CE, van Weely S, van Oers MH and Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994; 93: 1288-1292.
18. Aerts JM, Hollak C, Boot R and Groener A. Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. Philos Trans R Soc Lon B Biol Sci 2003; 385: 905-914. (Pubitemid 36639715)
19. Horner RJ, Zhu Z, Cohn L, Lee CG, White WI, Chen S, et al. Differential expression of chitinases identify subsets of murine airway epithelial cells in allergic inflammation. Am J Physiol Lung Cell Mol Physiol 2006; 291: L502-L511. (Pubitemid 44343728)
20. Hakala BE, White C and Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells is a mammalian member of chitinase protein family. J Biol Chem 1993; 268: 25803-23810.
21. Johansen JS, Milman N, Hansen M, Garbarsch C, Price PA and Graudal N. Increased serum YKL-40 in patients with pulmonary sarcoidosis -a potential marker of disease activity? Respir Med 2005; 99: 396-402. (Pubitemid 40347821)
22. Lee CG. Chitin, chitinases and chitinase-like proteins in allergic inflammation and tissue remodeling. Yonsei Med J 2009; 50: 22-30.
23. Sotgiu S, Barone R, Arru G, Fois ML, Pugliatti M, Sanna A, et al. Intrathecal chitotriosidase and the outcome of multiple sclerosis. Mult Scler 2006; 12: 551-557. (Pubitemid 46940627)
24. Comabella M, Dominguez C, Rio J, Martín-Gallán P, Vilches A, Vilarrasa N, et al. Plasma chitotriosidase activity in multiple sclerosis. Clin Immunol 2009; 131: 216-222.
25. Kronborg G, Ostergaard C, Weis N, Obel S, Pedersen SS, Price PA, et al. The serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated to the outcome of the disease. Scand J Infect Dis 2002; 34: 323-326. (Pubitemid 34746248)
26. Ostergaard C, Johansen JS, Benfield T, Price PA and Lundgren JD. YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin Diagn Lab Immunol 2002; 9: 598-604. (Pubitemid 34538220)
27. Jensen BV, Johansen JS and Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 2003; 9: 501-512.
28. Mitsuhashi A, Matsui H, Usui H, Nagai Y, Tate S, Unno Y, et al. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol 2009; 20: 71-77.
29. Vos K, Steenbakkers P, Miltenburg AM, Bos E, van den Heuvel MW, van Hogezand RA, et al. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2000; 59: 544-548. (Pubitemid 30445834)
30. Koutroubakis IE, Petinaki E, Dimoulios P, Vardas E, Roussomoustakaki M, Maniatis AN, et al. Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Colorectal Dis 2003; 18: 254-259. (Pubitemid 36764173)
31. Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. New Engl J Med 2007; 357: 2016-2027. (Pubitemid 350106709)
32. Bierbaum S, Nickel R, Koch A, Lau S, Deichmann KA, Wahn U, et al. Polymorphisms and haplotypes of acid mammalian chitinase are associated with bronchial asthma. Am J Respir Crit Care Med 2005; 172: 1505-1509. (Pubitemid 43076537)
33. Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. New Engl J Med 2008; 358: 1682-1691. (Pubitemid 351549915)
34. Vind I, Johansen JS, Price PA and Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol 2003; 38: 599-605. (Pubitemid 36724038)
35. Johansen JS, Jemsen HS and Price PA. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993; 32: 949-955. (Pubitemid 23334894)
36. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I and Price PA. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996; 35: 553-559.
37. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role of humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125: 1450-1461. (Pubitemid 34755161)
38. Correale J and Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 2004; 63: 2363-2370. (Pubitemid 40024351)
39. Zheng M, Cai WM, Zhao JK, Zhu SM and Liu RH. Determination of serum levels of YKL-40 and hyaluronic acid in patients with hepatic fibrosis due to schistosomiasis japonica and appraisal of their clinical value. Acta Trop 2005; 96: 148-152. (Pubitemid 41463745)
40. Kzhyshkowska J, Gratchev A and Goerdt S. Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark Insights 2007; 2: 128-146.
41. Sutherland TE, Maizels RM and Allen JE. Chitinase and chitinase-like proteins: potential therapeutic targets for the treatment of T-helper type 2 allergies. Clin Exp Allergy 2009; 39: 943-955.
42. Shuhui L, Mok YK and Wong WSF. Role of mammalian chitinases in asthma. Int Arch Allergy Immunol 2009; 149: 369-377.